181 related articles for article (PubMed ID: 21206493)
1. Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.
Shiirevnyamba A; Takahashi T; Shan H; Ogawa H; Yano S; Kanayama H; Izumi K; Uehara H
Br J Cancer; 2011 Feb; 104(3):505-13. PubMed ID: 21206493
[TBL] [Abstract][Full Text] [Related]
2. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
[TBL] [Abstract][Full Text] [Related]
7. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
9. Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche.
Ma Q; Liang M; Wu Y; Dou C; Xu J; Dong S; Luo F
J Extracell Vesicles; 2021 Feb; 10(4):e12068. PubMed ID: 33659051
[TBL] [Abstract][Full Text] [Related]
10. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
12. LPA Increases Tumor Growth and Bone Destruction Through Enhancement of Osteoclastogenic Cytokines.
Lindholm PF; Hwang YS
Anticancer Res; 2016 Jan; 36(1):61-70. PubMed ID: 26722028
[TBL] [Abstract][Full Text] [Related]
13. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
[TBL] [Abstract][Full Text] [Related]
14. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J; Weber K; Baranowsky A; Streichert T; Lange T; Spiro AS; Albers J; Seitz S; Zustin J; Amling M; Fehse B; Schinke T
Cancer Lett; 2012 Apr; 317(1):106-13. PubMed ID: 22108531
[TBL] [Abstract][Full Text] [Related]
15. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis.
Ohshiba T; Miyaura C; Ito A
Biochem Biophys Res Commun; 2003 Jan; 300(4):957-64. PubMed ID: 12559967
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
17. MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1α and H1.2.
Kim JM; Shin Y; Lee S; Kim MY; Punj V; Shin HI; Kim K; Koh JM; Jeong D; An W
Oncogene; 2018 Oct; 37(43):5749-5765. PubMed ID: 29925860
[TBL] [Abstract][Full Text] [Related]
18. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
19. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR
J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581
[TBL] [Abstract][Full Text] [Related]
20. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
